REPLY
23.10.2018 13:02:04 CEST | Business Wire | Press release
Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business.
Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA encourages innovation by Oracle PartnerNetwork (OPN) members, who use Oracle’s products and technology to create value for customers and generate new business potential.
Business Reply, the Reply Group company focused on Oracle SAAS, has been able to see the advantages of the Cloud in time and it has helped European companies to grasp the potential of the cloud, giving life to ambitious ERP cloud projects able to transform the business and services in depth.
Business Reply represents a point of reference among companies for ERP and Corporate Governance services, and it guarantees a deep knowledge of business processes together with a strong technical expertise on all Oracle application solutions.
Filippo Rizzante, CTO at Reply, said, “We are absolutely delighted to have won the award for Specialized Partner of the Year: ERPM Cloud – EMEA. Continuous investments in innovation and research & development have been critical to the creation of the most innovative ERP Cloud projects on Oracle technologies. The relationship and collaboration with Oracle has been instrumental to the success of Business Reply, enabling the team to maintain innovation as the Oracle platform evolves.”
“Business Reply has demonstrated an outstanding level of innovation in delivering proven, Oracle-based ERP Cloud solutions that solve our joint customers’ most critical business challenges,” said Javier Torres, Vice President Alliances & Channels Oracle EMEA. “We congratulate Business Reply in achieving the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. This achievement is a testament to their dedication to excellence and to providing customers solutions that drive real business value and results.”
About Business Reply
Business Reply, the Reply Group company specialising in the creation of integrated systems based on Oracle application suites, is Oracle Platinum Cloud Select Partner. With over 18 years of experience and more than 80 completed projects, Business Reply represents a point of reference among companies for ERP and Corporate Governance services. Strongly oriented towards Digital Transformation, thanks to investments in innovation and research & development and a process of continuous training and specialization of its resources, Business Reply was the first Italian Oracle Partner to realize projects on Oracle ERP Cloud, OTM Cloud and Service Cloud. In 2018, Business Reply has been recognized by Oracle: “Cloud Excellence Implementer”, for providing superior customer experience through successful Oracle HCM Cloud Services implementations.
About Oracle PartnerNetwork
Oracle PartnerNetwork (OPN) is Oracle's partner program that provides partners with a differentiated advantage to develop, sell and implement Oracle solutions. OPN offers resources to train and support specialized knowledge of Oracle’s products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to be recognized and rewarded for their investment in Oracle Cloud. Partners engaging with Oracle will be able to differentiate their Oracle Cloud expertise and success with customers through the OPN Cloud program – an innovative program that complements existing OPN program levels with tiers of recognition and progressive benefits for partners working with Oracle Cloud. To find out more visit: http://www.oracle.com/partners .
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005365/en/
Contact:
Reply Fabio Zappelli f.zappelli@reply.com or Aaron Miani a.miani@reply.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom